百利天恒(02615)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02615 百利天恒

待上市 12-19 16:00:00

0.000

+0.000

--

最高0.000	最低0.000	成交量0.00
今开0.000	昨收0.000	日振幅0.00%
总市值0.00	流通市值0.00	总股本4.22亿
成交额0.00	换手率0.00%	流通股本4.22亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"百利天恒","latestPrice":0,"timestamp":1766131200000,"preClose":0,"halted":7,"volume":0,"delay":0,"floatShares":421508117,"shares":421508117,"eps":0,"marketStatus":"待上市","change":0,"latestTime":"12-19 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":4102450200000},"marketStatusCode":8,"adr":0,"listingDate":4102416000000,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1766107800000,1766116800000],[1766120400000,1766131200000]],"volumeRatio":0,"ipoDetail":{"name":"百利天恒","exchange":"SEHK","listingDate":"2100-01-01","sharesOutstanding":421508117,"sharesFloat":421508117,"offerAmount":8634300,"priceRange":"347.500 - 389.000","market":"HK","openProspectusDate":"2025-11-07","openProspectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1107/2025110700014_c.pdf","purchaseBeginDate":"2025-11-07","purchaseEndDate":"2025-11-12","winningDate":"2025-11-14","currency":"HKD","minPurchaseQuantity":100,"peRate":39.25,"use":"1、约60.0%或1,810.5百万港元将用于拨付于中国内地以外地区的生物候选药物的研发活动；\n2、约30.0%或905.2百万港元将用于建立全球供应链，主要为在中国内地以外地区的生物候选药物的新生产设施的建设或潜在收购机会提供资金；\n3、约10.0%或301.7百万港元将用于拨付在中国内地以外业务的营运资金及其他一般公司用途。","industryId":"204005","industryName":"医疗保健","business":"公司是一家具备早期研发、临床开发、生产及商业化能力的综合医疗企业集团。","subscribed":19.93,"marketCap":146474000000,"minimumCapital":39292.31,"overAllotment":false,"lotSize":100,"issueOpenRate":0.1,"subscribeGear":"100,200,300,400,500,600,700,800,900,1000,1500,2000,2500,3000,3500,4000,4500,5000,6000,7000,8000,9000,10000,15000,20000,25000,30000,35000,40000,45000,50000,60000,70000,80000,90000,100000,150000,200000,300000,431700"},"greyMarketDetail":{"greyDate":"2099-12-31","greyDateTimestamp":4102329600000,"greyOpeningTime":4102388100000,"greyClosingTime":4102396200000,"showGreyQuote":false,"openProspectusDate":"2025-11-07","listingDate":"2100-01-01"},"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恒","latestPrice":354.62,"timestamp":1766127600000,"preClose":348.12,"halted":0,"volume":721400,"delay":0,"premium":"-100.00"}},"requestUrl":"/m/hq/s/02615","defaultTab":"news","newsList":[{"id":"2592064133","title":"2025年公募基金定增整体浮盈比例超32% 百利天恒、寒武纪成热门标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2592064133","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592064133?lang=zh_cn&edition=full","pubTime":"2025-12-19 08:17","pubTimestamp":1766103466,"startTime":"0","endTime":"0","summary":"若以17日收盘价计算，目前这些定增项目已实现浮盈112.24亿元，整体浮盈比例达32.93%。此外，中泰证券、昊华科技、爱旭股份、盛美上海和芯原股份这5只个股的公募定增获配金额也均突破10亿元，成为公募布局的重点标的。此外，交银施罗德基金和招商基金今年以来的定增投资也表现不俗，当前浮盈比例均超过50%。定增市场与二级市场关联紧密，财通基金预判，未来定增市场的供需格局将持续向好。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219081757a45d67dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219081757a45d67dd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["91194","02615"],"gpt_icon":0},{"id":"2592974802","title":"12月18日百利天恒现292.42万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2592974802","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592974802?lang=zh_cn&edition=full","pubTime":"2025-12-18 17:51","pubTimestamp":1766051502,"startTime":"0","endTime":"0","summary":"证券之星消息，12月18日百利天恒发生大宗交易，交易数据如下：大宗交易成交价格348.12元，成交0.84万股，成交金额292.42万元，买方营业部为华泰证券股份有限公司马鞍山湖东中路证券营业部，卖方营业部为中国国际金融股份有限公司北京建国门外大街证券营业部。近三个月该股共发生3笔大宗交易，合计成交1037.0手。截至2025年12月18日收盘，百利天恒报收于348.12元，下跌0.98%，换手率0.56%，成交量5768.0手，成交额2.03亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800027318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","BK0239","688506","91194"],"gpt_icon":0},{"id":"2592943229","title":"中国创新药领域已构成“黄金三角”，行业发展迎来强劲动能","url":"https://stock-news.laohu8.com/highlight/detail?id=2592943229","media":"制药网","labels":["economic"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592943229?lang=zh_cn&edition=full","pubTime":"2025-12-17 09:46","pubTimestamp":1765935968,"startTime":"0","endTime":"0","summary":"当前中国创新药产业正迎来历史性突破。而这一跨越的背后，业内指出，是研发投入做“加法”、审评审批流程做“减法”、市场空间做“乘法”构成的“黄金三角”正向循环，为创新药发展注入了强劲动能。此外，2025年至今，国内已批准上市的创新药达到69个，再创新高。其中，12月7日，国家医保局正式发布2025年国家医保目录和首版商保创新药目录，新增了114种药品纳入医保报销范围，包含50种1类创新药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217094734a4549957&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217094734a4549957&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","LU0359201885.HKD","BK1191","LU2543165471.USD","LU1023057109.AUD","LU0359201612.USD","BK1161","LU0359202008.SGD","02615","01276","06978"],"gpt_icon":0},{"id":"2591015695","title":"千亿市值创新药企俱乐部扩容！百济神州、百利天恒、信达生物等强势崛起","url":"https://stock-news.laohu8.com/highlight/detail?id=2591015695","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591015695?lang=zh_cn&edition=full","pubTime":"2025-12-15 09:51","pubTimestamp":1765763499,"startTime":"0","endTime":"0","summary":"根据数据统计，截至11月19日，A股和港股的千亿市值创新药企俱乐部已扩容至8家。其中，百济神州A股总市值超过4000亿元，百利天恒总市值超过1500亿元。港股千亿市值俱乐部包括百济神州、翰森制药、信达生物、康方生物等。其中，总市值超4000亿元的创新药企业百济神州已连续两个季度实现盈利。据悉，在研发方面，百济神州的研发管线也进入集中兑现阶段，未来18个月将迎来20项关键里程碑事件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215095603a44bddeb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215095603a44bddeb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1303224171.USD","LU0588546209.SGD","06978","BK1589","LU2242644610.SGD","LU0307460666.USD","LU1251922891.USD","BK1583","LU2097828474.EUR","03692","91194","LU1770034418.SGD","01801","LU2097828631.EUR","BK1574","BK1588","LU2097828714.EUR","BK1161","LU2097828557.USD","LU1719994722.HKD","LU2097828805.USD","LU0455707207.USD","LU0502904849.HKD","HK0000165453.HKD","LU2488822045.USD","06160","BK1500","LU2328871848.SGD","02615","LU1969619763.USD"],"gpt_icon":0},{"id":"2590598375","title":"四川新首富豪赌创新药：叫停港股IPO，百利天恒的“输血”与“造血”困局","url":"https://stock-news.laohu8.com/highlight/detail?id=2590598375","media":"中国能源网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590598375?lang=zh_cn&edition=full","pubTime":"2025-12-10 16:31","pubTimestamp":1765355518,"startTime":"0","endTime":"0","summary":"朱义的目标是将百利天恒打造为真正的跨国药企。而这已是百利天恒第三次冲击港股IPO。ALL IN创新药从三年连亏到年赚37亿元，再到前三季度亏损4.94亿元，百利天恒的业绩曲线堪称魔幻。创新药板块还未有产品上市，未形成收入。朱义的豪赌，全押在了即将上市的iza-bren上。这款被寄予厚望的药物，是百利天恒建立“造血”能力的关键，一旦iza-bren成功落地，或将改变公司依赖授权收入的现状。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121016332795353cb4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121016332795353cb4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","91194","02615","06978","BK1161"],"gpt_icon":0},{"id":"2589804345","title":"百利天恒公布HER2 ADC临床研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2589804345","media":"DoNews","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589804345?lang=zh_cn&edition=full","pubTime":"2025-12-07 21:39","pubTimestamp":1765114743,"startTime":"0","endTime":"0","summary":"2025年欧洲肿瘤内科学会亚洲年会（ESMO-Asia）上，百利天恒在大会口头报告中发布了其自主研发的HER2抗体药物偶联物T-Bren（BL-M07D1）的临床研究结果。该研究聚焦于HER2突变型晚期非小细胞肺癌（NSCLC）经治患者，数据显示T-Bren具有显著的抗肿瘤活性和良好安全性。此次发布标志着该创新药在精准治疗领域取得重要进展，有望为特定肺癌患者提供新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251207214113a7291dde&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251207214113a7291dde&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["91194","02615"],"gpt_icon":0},{"id":"2588018380","title":"百利天恒连放两个大招","url":"https://stock-news.laohu8.com/highlight/detail?id=2588018380","media":"药械Talks","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588018380?lang=zh_cn&edition=full","pubTime":"2025-12-03 09:47","pubTimestamp":1764726446,"startTime":"0","endTime":"0","summary":"短短几天时间，百利天恒连续放出两个大招。如今，凭借已在国内斩获12项适应症，特瑞普利单抗在2025年前三季度大卖近15亿元，同比增长40%。特别值得一提的是，截至2025年9月，百利天恒正在中国和美国就iza-bren开展40余项针对多种肿瘤类型的临床试验，其中正在中国开展11项不同癌种的III期临床注册研究，覆盖肺癌、乳腺癌、尿路上皮癌、食管癌和卵巢癌等多个实体瘤。如今，百利天恒的目标是成为在肿瘤治疗领域全球领先的MNC。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203103926a7206a24&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203103926a7206a24&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["91194","02615"],"gpt_icon":0},{"id":"2588188730","title":"百利天恒的惊险一跃","url":"https://stock-news.laohu8.com/highlight/detail?id=2588188730","media":"蓝筹企业评论","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588188730?lang=zh_cn&edition=full","pubTime":"2025-12-03 08:58","pubTimestamp":1764723512,"startTime":"0","endTime":"0","summary":"凭借一款名为BL-B01D1的明星ADC候选产品，百利天恒不仅与跨国巨头百时美施贵宝达成了总价值高达84亿美元的史诗级授权合作，其股价更是一路高歌。本文将从其转型之路、核心产品价值及平台潜力三个维度，深度剖析百利天恒如何完成这场“惊险一跃”，并试图解答其迈向跨国药企的征程能走多远。11月21日，CDE官网显示，百利天恒注射用BL-B01D1的上市申请已获受理，用于既往经PD-1/PD-L1单抗治疗且经至少两线化疗治疗失败的复发性或转移性鼻咽癌患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512030907529527b5e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512030907529527b5e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02615","91194"],"gpt_icon":0},{"id":"2588747143","title":"百利天恒又一里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=2588747143","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588747143?lang=zh_cn&edition=full","pubTime":"2025-12-01 14:13","pubTimestamp":1764569616,"startTime":"0","endTime":"0","summary":"近日，百利天恒宣布，收到由BMS支付的2.5亿美元里程碑付款。今年9月，百利天恒的全球Ⅱ/Ⅲ期关键注册临床试验IZABRIGHT-Breast01达成里程碑触发了该项付款。这是迄今为止已披露的国内创新药出海交易中，单个ADC资产首笔最大里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201154115a71c5193&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201154115a71c5193&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02615","91194"],"gpt_icon":0},{"id":"2588747117","title":"百利天恒、恒瑞、正大天晴同步全力推进HER2 ADC创新药！","url":"https://stock-news.laohu8.com/highlight/detail?id=2588747117","media":"创新药时代","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588747117?lang=zh_cn&edition=full","pubTime":"2025-12-01 10:19","pubTimestamp":1764555561,"startTime":"0","endTime":"0","summary":"百利天恒BL-M07D1则把火力投向HER2突变NSCLC。恒瑞医药SHR-A1811的亮点来自剂型革新。随着BTC、NSCLC等适应证数据成熟，国产HER2 ADC有望在2026年前后迎来密集上市潮，改写实体瘤后线格局。参考资料：1. 各家公司公告2. 百利天恒首次公布HER2 ADC非小细胞肺癌临床数据3. 恒瑞医药：SHR-A1811皮下注射版启动一期临床4. 正大天晴首次公布HER2双抗ADC药物胆道癌临床数据5. 药时代已发布文章6. 其它公开资料图片来源：药时代/公众号AI配图好管线，没出路，怎么办？","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201105532a71bd4aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201105532a71bd4aa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["91194","02615","06978","BK1574","BK1161"],"gpt_icon":0},{"id":"2588371664","title":"百利天恒收到里程碑付款；迈威生物披露阻塞性肺病新药临床进展｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2588371664","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588371664?lang=zh_cn&edition=full","pubTime":"2025-12-01 07:13","pubTimestamp":1764544408,"startTime":"0","endTime":"0","summary":"｜2025年12月1日星期一｜NO.1百利天恒收到百时美施贵宝里程碑付款百利天恒公告，子公司SystImmune已收到由百时美施贵宝支付的2.5亿美元里程碑付款。据合作协议，公司后续还有资格获得最高可达2.5亿美元的近期或有付款，以及在达到特定的开发、注册和销售里程碑后最高可达71亿美元的额外付款。合作协议中所约定的里程碑付款需要满足一定的条件，最终里程碑付款尚存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512013578546745.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512013578546745.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159938","BK1161","02615","91194","BK1515","BK1574","688506","688062","09939","BK0239"],"gpt_icon":0},{"id":"2587799680","title":"百利天恒(688506.SH)子公司收到与百时美施贵宝就iza-bren项目里程碑付款2.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2587799680","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2587799680?lang=zh_cn&edition=full","pubTime":"2025-11-30 16:56","pubTimestamp":1764492983,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)发布公告，公司全资子公司SystImmune近期收到由BMS支付的2.5亿美元里程碑付款。根据合作协议，公司后续还有资格获得最高可达2.5亿美元的近期或有付款，以及在达到特定的开发、注册和销售里程碑后最高可达71亿美元的额外付款。合作协议中所约定的里程碑付款需要满足一定的条件，最终里程碑付款尚存在不确定性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0306806265.USD","688506","LU1868837136.USD","LU1032466523.USD","LU0306807586.USD","LU0114720955.EUR","BK4585","BK4007","LU0321505439.SGD","IE00B2B36J28.USD","LU0868494617.USD","IE0002141913.USD","LU2242646821.SGD","LU1868837300.USD","LU1670711123.USD","LU2125154935.USD","LU2133065610.SGD","LU1074936037.SGD","LU1868836914.USD","BMY","BK0239","LU2242652126.USD","LU1868836591.USD","LU2360032135.SGD","IE00BFTCPJ56.SGD","LU1868836757.USD","91194","LU0096364046.USD","02615","LU0225771236.USD","BK4581","LU1430594728.SGD","BK4532","LU0882574055.USD","IE00BJJMRZ35.SGD","LU1670710661.SGD","BK4559","LU1323610961.USD","LU1670710588.SGD","LU1718418525.SGD","LU0267386448.USD","LU1093756168.USD","LU0985481810.HKD","LU1291159041.SGD","BK4588","IE00BJT1NW94.SGD","LU1261432733.SGD","LU1093756325.SGD","LU1585245621.USD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2586722547","title":"百利天恒（688506）披露召开2025年第三季度业绩说明会公告，11月27日股价下跌0.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586722547","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586722547?lang=zh_cn&edition=full","pubTime":"2025-11-27 22:32","pubTimestamp":1764253945,"startTime":"0","endTime":"0","summary":"截至2025年11月27日收盘，百利天恒报收于384.99元，较前一交易日下跌0.85%，最新总市值为1589.52亿元。公司近日发布公告称，四川百利天恒药业股份有限公司将于2025年12月4日15:00-16:00通过上证路演中心以网络文字互动方式召开2025年第三季度业绩说明会，介绍公司经营成果、财务状况及发展战略。投资者可于2025年11月28日至12月3日16:00前通过上证路演中心预提问栏目或公司邮箱ir@baili-pharm.com提交问题。说明会结束后可通过上证路演中心查看会议内容。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700038707.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","BK0239","02615","91194"],"gpt_icon":1},{"id":"2586260666","title":"研报点睛：涨幅居前！关注这一赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2586260666","media":"东方财富研究中心","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586260666?lang=zh_cn&edition=full","pubTime":"2025-11-26 17:35","pubTimestamp":1764149725,"startTime":"0","endTime":"0","summary":"11月26日，A股三大指数今日涨跌不一，截止收盘，沪指跌0.15%，收报3864.18点；深证成指涨1.02%，收报12907.83点；创业板指涨2.14%，收报3044.69点。国金证券表示，CGT 等前沿创新，或迎监管更多支持；数据生态新赛道，隐藏未来新金矿。颠覆性创新技术赛道的布局，将是未来药企制胜要地。新一代技术的细胞基因疗法、AI制药等前沿赛道，或是2026年新热点。医药医疗数据要素相关企业，值得药企布局和资本市场关注与投资。国泰海通表示，持续推荐创新药械及产业链。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126174028a4bb8740&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126174028a4bb8740&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","03347","BK1191","LU2543165471.USD","02615","01276","LU1023057109.AUD","LU0359202008.SGD","LU0359201612.USD","LU0359201885.HKD","06990","02359"],"gpt_icon":0},{"id":"2586475897","title":"百利天恒：截至2025年9月30日，股东户数为5979户","url":"https://stock-news.laohu8.com/highlight/detail?id=2586475897","media":"证券日报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586475897?lang=zh_cn&edition=full","pubTime":"2025-11-25 21:07","pubTimestamp":1764076026,"startTime":"0","endTime":"0","summary":"证券日报网讯百利天恒11月25日在互动平台回答投资者提问时表示，截至2025年9月30日，股东户数为5，979户。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511253574450719.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","688506","BK0239","02615"],"gpt_icon":0},{"id":"2586872382","title":"成都温江：两家药企上榜“中国创新力企业50强”","url":"https://stock-news.laohu8.com/highlight/detail?id=2586872382","media":"中国经济时报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586872382?lang=zh_cn&edition=full","pubTime":"2025-11-25 14:22","pubTimestamp":1764051769,"startTime":"0","endTime":"0","summary":"图片来源/温江区投资促进局■中国经济时报记者王彩娜 ■韩清华 张丽近日，福布斯中国发布“2025中国创新力企业50强”榜单，全国共有8家医药企业入选，其中，温江两家企业百利天恒和科伦博泰上榜。据了解，科伦博泰积极融入行业趋势，与默沙东等全球制药公司深度合作，充分嫁接全球资源，高效兑现创新价值，成为中国药企全球化创新的标杆。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251125142705a4b8b8d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251125142705a4b8b8d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06990","02615","LU0196878994.USD"],"gpt_icon":0},{"id":"2586089497","title":"创新药出海的下一个重点是把药卖好","url":"https://stock-news.laohu8.com/highlight/detail?id=2586089497","media":"界面","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586089497?lang=zh_cn&edition=full","pubTime":"2025-11-24 18:20","pubTimestamp":1763979634,"startTime":"0","endTime":"0","summary":"iza-bren是诸多同类首创级别中国创新药中的一个，这类产品不断向上市阶段迈进，意味着中国创新药的水平在不断提升。不过，自今年年中起，创新药板块持续回调。他表示，对于中国药企而言，避开国内的同质化竞争，将产品海外授权，利用大药企的商业化能力弥补自身缺点，目前来看是较为正确的道路。他认为，药品出海到国际化的市场，主要还是为了支持药品国际化的高成本研发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124182418977c5077&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124182418977c5077&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828714.EUR","HK0000165453.HKD","LU2097828631.EUR","LU2097828805.USD","02615","LU2097828557.USD","BK1574","LU0455707207.USD","LU2097828474.EUR","LU2328871848.SGD","BK1589","01801","LU2488822045.USD","LU2242644610.SGD","BK1161","LU0502904849.HKD","LU1969619763.USD","06978","BK1583"],"gpt_icon":0},{"id":"2586445224","title":"仿制药企转型的10个案例","url":"https://stock-news.laohu8.com/highlight/detail?id=2586445224","media":"药融CDMO之家","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586445224?lang=zh_cn&edition=full","pubTime":"2025-11-24 15:31","pubTimestamp":1763969513,"startTime":"0","endTime":"0","summary":"“最靓的仔”只是极少数，更多的仿制药企业自觉地划分界线、自觉地站到了“技术落后”“竞争激烈”的一边，这是战略大错！石药集团以抗生素、心脑血管仿制药起家，转型后2024年创新药核心产品多美素、津优力、玄宁合计销售额超100亿元。列举了这么多，是想说明仿制药企也能玩转创新药，很多创新药明星企业，过去都曾是仿制药企业，只要肯转型，就有可能实现新突破，这也是为数众多的、身处激烈竞争市场的仿制药企业的一条出路。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124175442a4b6d636&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124175442a4b6d636&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06978","BK1161","02615"],"gpt_icon":0},{"id":"2585175812","title":"辉瑞血友病新药在华获批，百利天恒双抗ADC报产，信立泰降脂新药获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2585175812","media":"医药经济报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585175812?lang=zh_cn&edition=full","pubTime":"2025-11-21 18:36","pubTimestamp":1763721389,"startTime":"0","endTime":"0","summary":"百利天恒双抗ADC上市申请获受理11月21日，CDE官网显示，百利天恒注射用BL-B01D1上市申请获受理。业内推测，本次申报的适应症或为鼻咽癌。2023年12月，百利天恒与BMS达成独家许可与合作协议，在全球范围内进行共同开发和商业化BL-B01D1。信立泰降脂创新药获批临床11月21日，信立泰公告称，已收到NMPA核准签发的《临床试验批准通知书》，同意其自主研发的创新小分子药物SAL0139片开展治疗高脂血症的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251121191728a4b181e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251121191728a4b181e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02615","91194"],"gpt_icon":0},{"id":"2585513197","title":"百利天恒获80亿授信，暂缓IPO后继续“输血”国际化","url":"https://stock-news.laohu8.com/highlight/detail?id=2585513197","media":"界面","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585513197?lang=zh_cn&edition=full","pubTime":"2025-11-21 15:29","pubTimestamp":1763710194,"startTime":"0","endTime":"0","summary":"此前一周，百利天恒刚刚宣布“鉴于目前的市场情况”，延迟港股全球发售及上市。今年9月，百利天恒完成前述定增，并第三次更新港股招股书。以此看来，百利天恒始终“十分缺钱”。界面新闻截自百利天恒2025年中报以上布局无疑将快速大量“烧钱”。百利天恒近年研发费用及同比变动。辉瑞称，近期将对PF-08634404展开第一波7项临床研究，包括2项分别针对非小细胞肺癌和结直肠癌的全球III期研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112115323095123046&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112115323095123046&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02615","91194"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.baili-pharm.com","compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0054},{"period":"3month","weight":-0.0322},{"period":"6month","weight":0.0918},{"period":"1year","weight":0.3006},{"period":"ytd","weight":0.2807}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"公司是一家聚焦于全球生物医药前沿领域，立足于解决临床未被满足的需求，具备包括小分子化学药、大分子生物药及ADC药物的全系列药品研究开发能力，并拥有从中间体、原料药到制剂一体化优势的、覆盖“研发—生产—营销”完整全生命周期商业化运营能力的生物医药企业。公司拥有两大业务板块,分别为创新生物药业务和化药制剂、中成药制剂业务板块。公司主要产品:丙泊酚乳状注射液、丙泊酚中/长链脂肪乳注射液、吸入用七氟烷、结构脂肪乳注射液(C6~24)、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。","exchange":"SEHK","name":"百利天恒","nameEN":"BIOKIN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百利天恒(02615)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百利天恒(02615)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百利天恒,02615,百利天恒股票,百利天恒股票老虎,百利天恒股票老虎国际,百利天恒行情,百利天恒股票行情,百利天恒股价,百利天恒股市,百利天恒股票价格,百利天恒股票交易,百利天恒股票购买,百利天恒股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百利天恒(02615)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百利天恒(02615)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}